

Paola Fioretto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8830020/publications.pdf>

Version: 2024-02-01

84
papers

6,239
citations

109321

35
h-index

69250

77
g-index

87
all docs

87
docs citations

87
times ranked

7140
citing authors

#	ARTICLE	IF	CITATIONS
1	Expanding the therapy options for diabetic kidney disease. <i>Nature Reviews Nephrology</i> , 2022, 18, 78-79.	9.6	10
2	In hospital risk factors for acute kidney injury and its burden in patients with Sars-Cov-2 infection: a longitudinal multinational study. <i>Scientific Reports</i> , 2022, 12, 3474.	3.3	8
3	Sodium-glucose co-transporter ² inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practice. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1187-1196.	4.4	12
4	Time-series analysis of multidimensional clinical-laboratory data by dynamic Bayesian networks reveals trajectories of COVID-19 outcomes. <i>Computer Methods and Programs in Biomedicine</i> , 2022, 221, 106873.	4.7	3
5	Cardiac injury and mortality in patients with Coronavirus disease 2019 (COVID-19): insights from a mediation analysis. <i>Internal and Emergency Medicine</i> , 2021, 16, 419-427.	2.0	31
6	SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. <i>American Journal of Kidney Diseases</i> , 2021, 77, 94-109.	1.9	88
7	SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. <i>Diabetes</i> , 2021, 70, 1-16.	0.6	53
8	SGLT2 Inhibitors and the Clinical Implications of Associated Weight Loss in Type 2 Diabetes: A Narrative Review. <i>Diabetes Therapy</i> , 2021, 12, 2249-2261.	2.5	18
9	Effectiveness of In-Hospital Cholecalciferol Use on Clinical Outcomes in Comorbid COVID-19 Patients: A Hypothesis-Generating Study. <i>Nutrients</i> , 2021, 13, 219.	4.1	56
10	Sudden death with massive hemoptysis from aortobronchial fistula. <i>Cardiovascular Pathology</i> , 2020, 44, 107158.	1.6	1
11	SGLT2 inhibitors to prevent diabetic kidney disease. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 4-5.	11.4	9
12	Long-term blood pressure variability, incidence of hypertension and changes in renal function in type 2 diabetes. <i>Journal of Hypertension</i> , 2020, 38, 2279-2286.	0.5	11
13	The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: The Padua province experience. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2629-2635.	3.8	71
14	Blood pressure reduction and RAAS inhibition in diabetic kidney disease: therapeutic potentials and limitations. <i>Journal of Nephrology</i> , 2020, 33, 949-963.	2.0	31
15	Renal structure in type 2 diabetes: facts and misconceptions. <i>Journal of Nephrology</i> , 2020, 33, 901-907.	2.0	20
16	Indications for renal biopsy in patients with diabetes. Joint position statement of the Italian Society of Nephrology and the Italian Diabetes Society. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 2123-2132.	2.6	9
17	Diabetic kidney disease: the onset of a new era?. <i>Journal of Nephrology</i> , 2020, 33, 899-900.	2.0	5
18	Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration. <i>Diabetes Research and Clinical Practice</i> , 2020, 168, 108374.	2.8	147

#	ARTICLE	IF	CITATIONS
19	Obesity and COVID-19: An Italian Snapshot. <i>Obesity</i> , 2020, 28, 1600-1605.	3.0	135
20	Exposure to dipeptidyl-peptidase-4 inhibitors and COVID-19 among people with type 2 diabetes: A case-control study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1946-1950.	4.4	91
21	High-protein diet: A barrier to the nephroprotective effects of sodium-glucose cotransporter-2 inhibitors?. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1511-1515.	4.4	4
22	Atherogenic dyslipidemia and diabetic nephropathy. <i>Journal of Nephrology</i> , 2020, 33, 1001-1008.	2.0	36
23	SARS-CoV-2 RNA identification in nasopharyngeal swabs: issues in pre-analytics. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 1579-1586.	2.3	49
24	Characterization of subcutaneous and omental adipose tissue in patients with obesity and with different degrees of glucose impairment. <i>Scientific Reports</i> , 2019, 9, 11333.	3.3	48
25	Overall Quality of Care Predicts the Variability of Key Risk Factors for Complications in Type 2 Diabetes: An Observational, Longitudinal Retrospective Study. <i>Diabetes Care</i> , 2019, 42, 514-519.	8.6	28
26	Long-term blood pressure variability and development of chronic kidney disease in type 2 diabetes. <i>Journal of Hypertension</i> , 2019, 37, 805-813.	0.5	23
27	Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable. <i>European Heart Journal</i> , 2019, 40, 2907-2919.	2.2	32
28	Natural history and risk factors for diabetic kidney disease in patients with T2D: lessons from the AMD-annals. <i>Journal of Nephrology</i> , 2019, 32, 517-525.	2.0	30
29	Changes in albuminuria and renal outcome in patients with type 2 diabetes and hypertension. <i>Journal of Hypertension</i> , 2018, 36, 1719-1728.	0.5	10
30	Apparent Treatment Resistant Hypertension, Blood Pressure Control and the Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes. <i>Kidney and Blood Pressure Research</i> , 2018, 43, 422-438.	2.0	19
31	Association of kidney disease measures with risk of renal function worsening in patients with type 1 diabetes. <i>BMC Nephrology</i> , 2018, 19, 347.	1.8	2
32	Five-Year Predictors of Insulin Initiation in People with Type 2 Diabetes under Real-Life Conditions. <i>Journal of Diabetes Research</i> , 2018, 2018, 1-10.	2.3	13
33	Diabetic kidney disease in the elderly: prevalence and clinical correlates. <i>BMC Geriatrics</i> , 2018, 18, 38.	2.7	47
34	Normoalbuminuric kidney impairment in patients with T1DM: insights from annals initiative. <i>Diabetology and Metabolic Syndrome</i> , 2018, 10, 60.	2.7	15
35	Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2532-2540.	4.4	133
36	Role of incretin based therapies in the treatment of diabetic kidney disease. <i>Diabetes Mellitus</i> , 2018, 21, 395-398.	1.9	2

#	ARTICLE	IF	CITATIONS
37	The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects. <i>Diabetologia</i> , 2017, 60, 395-398.	6.3	34
38	Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 517-527.	1.8	5
39	Variability in <sc>HbA1c</sc>, blood pressure, lipid parameters and serum uric acid, and risk of development of chronic kidney disease in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1570-1578.	4.4	70
40	Mechanisms linking empagliflozin to cardiovascular and renal protection. <i>International Journal of Cardiology</i> , 2017, 241, 450-456.	1.7	36
41	Epidemiology of diabetic kidney disease in adult patients with type 1 diabetes in Italy: The AMD Annals initiative. <i>Diabetes/Metabolism Research and Reviews</i> , 2017, 33, e2873.	4.0	26
42	Resistant Hypertension, Time-Updated Blood Pressure Values and Renal Outcome in Type 2 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	21
43	Predictors of chronic kidney disease in type 1 diabetes: a longitudinal study from the AMD Annals initiative. <i>Scientific Reports</i> , 2017, 7, 3313.	3.3	23
44	Association of kidney disease measures with risk of renal function worsening in patients with hypertension and type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 419-426.	2.3	22
45	Metabolic syndrome, serum uric acid and renal risk in patients with T2D. <i>PLoS ONE</i> , 2017, 12, e0176058.	2.5	25
46	Antihyperglycemic treatment in patients with type 2 diabetes in Italy: the impact of age and kidney function. <i>Oncotarget</i> , 2017, 8, 62039-62048.	1.8	7
47	Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies. <i>Drugs and Aging</i> , 2016, 33, 511-522.	2.7	32
48	Plasma Triglycerides and HDL-C Levels Predict the Development of Diabetic Kidney Disease in Subjects With Type 2 Diabetes: The AMD Annals Initiative. <i>Diabetes Care</i> , 2016, 39, 2278-2287.	8.6	93
49	SGLT2 Inhibitors and the Diabetic Kidney. <i>Diabetes Care</i> , 2016, 39, S165-S171.	8.6	279
50	Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment. <i>Diabetologia</i> , 2016, 59, 2036-2039.	6.3	78
51	Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies. <i>Canadian Journal of Diabetes</i> , 2016, 40, 247-257.	0.8	18
52	The effect of dapagliflozin on renal function in patients with type 2 diabetes. <i>Journal of Nephrology</i> , 2016, 29, 391-400.	2.0	62
53	Glomerular structural-functional relationship models of diabetic nephropathy are robust in type 1 diabetic patients. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 918-923.	0.7	38
54	Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2015, 14, 142.	6.8	68

#	ARTICLE	IF	CITATIONS
55	The Authors Reply:. <i>Kidney International</i> , 2014, 86, 1272.	5.2	0
56	Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. <i>Kidney International</i> , 2014, 85, 962-971.	5.2	532
57	Is diabetic nephropathy reversible?. <i>Diabetes Research and Clinical Practice</i> , 2014, 104, 323-328.	2.8	29
58	Pancreas Transplantation and Reversal of Diabetic Nephropathy Lesions. <i>Medical Clinics of North America</i> , 2013, 97, 109-114.	2.5	17
59	Renal Structure in Normoalbuminuric and Albuminuric Patients With Type 2 Diabetes and Impaired Renal Function. <i>Diabetes Care</i> , 2013, 36, 3620-3626.	8.6	178
60	Reversal of diabetic nephropathy: lessons from pancreas transplantation. <i>Journal of Nephrology</i> , 2012, 25, 13-18.	2.0	39
61	Tacrolimus and Cyclosporine Nephrotoxicity in Native Kidneys of Pancreas Transplant Recipients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 101-106.	4.5	38
62	Residual microvascular risk in diabetes: unmet needs and future directions. <i>Nature Reviews Endocrinology</i> , 2010, 6, 19-25.	9.6	92
63	Diabetic nephropathyâ€™ challenges in pathologic classification. <i>Nature Reviews Nephrology</i> , 2010, 6, 508-510.	9.6	59
64	Bariatric Surgery Improves Atherogenic LDL Profile by Triglyceride Reduction. <i>Obesity Surgery</i> , 2009, 19, 190-195.	2.1	32
65	The kidney in type 2 diabetes: focus on renal structure. <i>Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion</i> , 2009, 56, 18-20.	0.8	2
66	Histopathology of Diabetic Nephropathy. <i>Seminars in Nephrology</i> , 2007, 27, 195-207.	1.6	379
67	Diabetic nephropathy: An update on renal structure. <i>International Congress Series</i> , 2007, 1303, 51-59.	0.2	4
68	Renal Protection in Diabetes: Role of Glycemic Control. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, S86-S89.	6.1	98
69	Enhancing the Predictive Value of Urinary Albumin for Diabetic Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 339-352.	6.1	86
70	Antihypertensive Treatment and Multifactorial Approach for Renal Protection in Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, S18-S21.	6.1	27
71	Diabetic nephropathy: renal structural studies in type 1 and type 2 diabetic patients. <i>International Congress Series</i> , 2003, 1253, 163-169.	0.2	13
72	Is Podocyte Injury Relevant in Diabetic Nephropathy?. <i>Diabetes</i> , 2003, 52, 1031-1035.	0.6	273

#	ARTICLE	IF	CITATIONS
73	Low Glomerular Filtration Rate in Normoalbuminuric Type 1 Diabetic Patients. <i>Diabetes</i> , 2003, 52, 1036-1040.	0.6	273
74	The Angiotensin-Converting Enzyme DD Genotype Is Associated With Glomerulopathy Lesions in Type 2 Diabetes. <i>Diabetes</i> , 2002, 51, 251-255.	0.6	43
75	Risk predictors in patients with diabetic nephropathy. <i>Current Diabetes Reports</i> , 2001, 1, 245-250.	4.2	3
76	VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTORS IN DIABETIC NEPHROPATHY: EXPRESSION STUDIES IN BIOPSIES OF TYPE 2 DIABETIC PATIENTS. <i>Renal Failure</i> , 2001, 23, 483-493.	2.1	16
77	A Defect in Glycogen Synthesis Characterizes Insulin Resistance in Hypertensive Patients With Type 2 Diabetes. <i>Hypertension</i> , 2001, 37, 1492-1496.	2.7	15
78	Insulin-dependent diabetic sibling pairs are concordant for sodium-hydrogen antiport activity ¹¹ See Editorial by Giancarlo Viberti, p. 2526.. <i>Kidney International</i> , 1999, 55, 2383-2389.	5.2	29
79	Proximal tubular basement membrane width in insulin-dependent diabetes mellitus. <i>Kidney International</i> , 1998, 53, 754-761.	5.2	121
80	Reversal of Lesions of Diabetic Nephropathy after Pancreas Transplantation. <i>New England Journal of Medicine</i> , 1998, 339, 69-75.	27.0	1,084
81	Growth phenotype of cultured skin fibroblasts from IDDM patients with and without nephropathy and overactivity of the Na ⁺ /H ⁺ antiporter. <i>Kidney International</i> , 1996, 50, 1684-1693.	5.2	36
82	Cyclosporine associated lesions in native kidneys of diabetic pancreas transplant recipients. <i>Kidney International</i> , 1995, 48, 489-495.	5.2	51
83	Sequential renal biopsies in insulin-dependent diabetic patients: Structural factors associated with clinical progression. <i>Kidney International</i> , 1995, 48, 1929-1935.	5.2	121
84	Renal interstitial expansion in insulin-dependent diabetes mellitus. <i>Kidney International</i> , 1993, 43, 661-667.	5.2	203